. 2012 Mar 1;2(4):334–342. doi: 10.1007/s13193-012-0139-1

Table 1.

Practice changing clinical trials in operable gastric cancer

Trial Name	Intervention (no of patients)	5-year overall survival	HR (95% confidence intervals), P value
Intergroup 0116[28]	Surgery(277)	41%	1.31 (1.09–1.59)
Intergroup 0116[28]	Surgery + Adjuvant 5FU/LV chemoradiation (282)	50%	p = 0.005
MAGIC[3]	Perioperative chemotherapy + surgery (253)	36.3%	0.75 (0.60–0.93)
MAGIC[3]	Surgery (250)	23.0%	p = 0.009
FFCD[36]	Perioperative chemotherapy + surgery (113)	38%	0.69 (0.50–0.95)
FFCD[36]	Surgery (111)	24%	p = 0.003
ACTS-GC[25]	Adjuvant S-1 (529)	72.6%	HR 0.65 (0.53–0.81)
ACTS-GC[25]	Observation (530)	61.4%	HR 0.65 (0.53–0.81)
CLASSIC[24]*	Adjuvant CAPOX (520)*	74%	HR 0.56; (0.44–0.72)
CLASSIC[24]*	Observation(515)*	60%	p < 0.0001

* Survival values given for CLASSIC study are for 3-year disease free survival